Slide Show: Trends in Targeted Therapies and Immunotherapies

A phase 3 trial evaluating frontline IFx-2.0 with pembrolizumab in advanced/metastatic Merkel cell carcinoma is planned to start later in June 2025.

Georgios Evangelou, MD, MSc, speaks to the potential utility of neoadjuvant capecitabine/temozolomide in well-differentiated atypical carcinoids.

Data from the IGNYTE trial demonstrate the development of a robust systemic antitumor response following treatment with RP1.

Rian M. Hasson Charles, MD, MPH, FACS, discusses advances in equitable lung cancer screening and her experiences as a woman in thoracic oncology.

THIO with cemiplimab is active and well-tolerated in patients with advanced non–small cell lung cancer resistant to immune checkpoint inhibitors in second- and third-line settings.

The median OS was 18.5 months in those who received 6 or more cycles of induction chemotherapy vs 13.1 months in those who did not.